Compare GLW & SNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GLW | SNY |
|---|---|---|
| Founded | 1851 | 1994 |
| Country | United States | France |
| Employees | N/A | 74846 |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 149.7B | 104.5B |
| IPO Year | 2008 | N/A |
| Metric | GLW | SNY |
|---|---|---|
| Price | $177.18 | $44.15 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 12 | 5 |
| Target Price | ★ $146.91 | $58.00 |
| AVG Volume (30 Days) | ★ 10.2M | 2.3M |
| Earning Date | 04-28-2026 | 04-23-2026 |
| Dividend Yield | 0.74% | ★ 3.47% |
| EPS Growth | ★ 215.52 | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | ★ $15,629,000,000.00 | N/A |
| Revenue This Year | $20.74 | $3.49 |
| Revenue Next Year | $12.80 | $6.10 |
| P/E Ratio | $391.35 | ★ $6.14 |
| Revenue Growth | ★ 19.14 | N/A |
| 52 Week Low | $49.47 | $42.28 |
| 52 Week High | $211.79 | $52.68 |
| Indicator | GLW | SNY |
|---|---|---|
| Relative Strength Index (RSI) | 47.73 | 51.69 |
| Support Level | $171.11 | $42.30 |
| Resistance Level | $177.92 | $48.76 |
| Average True Range (ATR) | 11.93 | 0.60 |
| MACD | -3.11 | 0.16 |
| Stochastic Oscillator | 26.07 | 75.00 |
Corning is a provider of glass, ceramics, and optical fiber across six distinct end markets. Corning's largest segments by revenue are display glass for TVs and optical fiber for telecom networks and data centers. It also provides cover glass for smartphones as well as filters and substrates and glass for cars, produces pharmaceutical glass, and produces polysilicon for solar panels. Corning is a US producer and is vertically integrated across its products and markets.
Sanofi develops and markets drugs with a concentration in immunology, vaccines, and rare diseases. Although the company offers a diverse array of drugs, its highest revenue generator, Dupixent, accounts for over 30% of total sales. Profits for this immunology blockbuster drug are shared with Regeneron. About 45% of total revenue comes from the United States, 20% from Europe, and 6% from China.